Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Go back to Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
(NYSE: BHVN) Delayed: 11.75 -0.06 (0.51%)
Previous Close $11.81    52 Week High $ 
Open $11.90    52 Week Low $ 
Day High $12.16    P/E N/A 
Day Low $11.63    EPS $ 
Volume 1,443,718